Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Human Immunodeficiency Virus Infection (HIV) Clear all
Completed Phase 1Phase 2 Interventional Results available

Autologous Dendritic Cell Vaccine in HIV1 Infection

NCT00510497
View directory record Official record
Conditions
HIV Infections
Interventions
Autologous HIV-1 ApB DC Vaccine
Biological
Lead sponsor
Sharon Riddler
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional Results available

TAKE Steps: Motivational Interviewing to Prevent STIs

NCT05215262
View directory record Official record
Conditions
Self Efficacy, HIV Prevention, STI Prevention
Interventions
Treat Act Know Engage (T.A.K.E.) Steps, Standard or Care
Behavioral
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
13 Years to 19 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
5
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 2 Interventional

The Effects of Giving Interleukin-2 (IL-2) Plus Anti-HIV Therapy to HIV-Positive Patients With CD4 Cell Counts of at Least 350 Cells/mm3

NCT00000825
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational

Collection of Samples From HIV-1 Infected Individuals for Evaluation of the Aptima HIV-1 Assay

NCT02026752
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Not listed
Lead sponsor
Gen-Probe, Incorporated
Industry
Eligibility
15 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
9
States / cities
Palm Springs, California • San Diego, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2017 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational

Body Image in Youth With HIV

NCT01673750
View directory record Official record
Conditions
Human Immunodeficiency Virus, HIV
Interventions
Questionnaire
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
16 Years to 23 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2014 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional

Fosamprenavir Versus Other Protease Inhibitors

NCT00094523
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus I
Interventions
Fosamprenavir
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
51
States / cities
Beverly Hills, California • Fresno, California • Laguna Beach, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional

Antiretroviral Therapy Adherence and Secondary Prevention of Human Immunodeficiency Virus

NCT01760759
View directory record Official record
Conditions
HIV
Interventions
cell phone reminders, contingency management for adherence
Behavioral
Lead sponsor
UConn Health
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
2
States / cities
Farmington, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational

Use of Bromodeoxyuridine to Study White Blood Cell Replication and Survival in HIV-Infected Patients

NCT00001650
View directory record Official record
Conditions
HIV Infection, Acquired Immunodeficiency Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 23, 2026, 4:33 AM EDT
Not listed Phase 1 Interventional

Safety Study of the HemoModulator System for the Treatment of Patients With Human Immunodeficiency Virus (HIV)

NCT00858923
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Energex HemoModulator
Device
Lead sponsor
Energex Systems, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2009 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Immunogenicity Study of Different Vaccine Schedules With Ad26.Mos.HIV and Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults

NCT02685020
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos.HIV, Clade C gp140, Placebo
Biological · Drug
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection

NCT00002176
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

GSK1349572 Relative Bioavailability Study

NCT01098513
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK1349572 formulation AP, GSK1349572 formulation AW, GSK1349572 formulation AX
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2017 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Vitamin D and Effect on Heart Disease and Insulin Resistance

NCT01093417
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV), Vitamin D Deficiency, HIV Infections
Interventions
Vitamin D, Placebo
Drug · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 2 Interventional

Effects of Creatine and Resistance Exercise Training in People With HIV Infection

NCT00484627
View directory record Official record
Conditions
HIV Infections
Interventions
Use of creatine monohydrate (a dietary supplement), Progressive resistance exercise training
Procedure · Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2007 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional

An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy

NCT00002089
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Day and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Groton, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational

Redistribution of Fat and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)

NCT00244803
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 30, 2016 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mobile Enhanced Prevention Support for People Leaving Jail

NCT04036396
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Diseases, Bacterial, Hepatitis C, Substance Use Disorders
Interventions
Mobile Enhanced Prevention Support, Usual Care plus Customized Referrals
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
233 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
3
States / cities
Los Angeles, California • Santa Fe Springs, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

NCT02469246
View directory record Official record
Conditions
HIV-1 Infection
Interventions
F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
34
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2019 · Synced Jul 23, 2026, 4:33 AM EDT
Completed No phase listed Observational Results available

Development of a Health-Related Symptom Index for Participants With and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions

NCT04276935
View directory record Official record
Conditions
High Grade Anal Canal Squamous Intraepithelial Neoplasia, Human Immunodeficiency Virus
Interventions
Interview, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Regimen Versus Boosted Protease Inhibitor (bPI) Along With Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) Regimen in Virologically-Suppressed, HIV-1 Infected Participants

NCT02269917
View directory record Official record
Conditions
Human Immunodeficiency Virus Type 1
Interventions
D/C/F/TAF, Boosted Protease Inhibitor (bPI), FTC/TDF
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years and older
Enrollment
1,149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
38
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 2 Interventional

A Study to Compare Two Anti-HIV Combination Therapies Each Containing Saquinavir in HIV-Positive Children

NCT00000913
View directory record Official record
Conditions
HIV Infections
Interventions
Ritonavir, Nelfinavir mesylate, Saquinavir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 16 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2001
U.S. locations
33
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Drug Interaction Between Dolutegravir (DTG) and Daclatasvir (DCV) in Healthy Adult Subjects

NCT02082808
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
DTG, DCV
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Project PRIDE (Promoting Resilience In Discriminatory Environments)

NCT03528135
View directory record Official record
Conditions
Human Immunodeficiency Virus, Sexually Transmitted Infections, Anxiety, Depression, Substance Use Disorders
Interventions
Project PRIDE
Behavioral
Lead sponsor
University of Houston
Other
Eligibility
18 Years to 25 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 24, 2022 · Synced Jul 23, 2026, 4:33 AM EDT
Completed Phase 3 Interventional

A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients

NCT00002140
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ethambutol hydrochloride, Clarithromycin, Azithromycin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
24
States / cities
Berkeley, California • Mill Valley, California • Oakland, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 23, 2026, 4:33 AM EDT